Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis

被引:0
|
作者
Meng, Fanqiao [1 ]
Xiang, Maoyuan [1 ]
Liu, Yu [1 ]
Zeng, Dongfeng [1 ]
机构
[1] Third Mil Med Univ, Army Med Univ, Daping Hosp, Dept Hematol, 10 Daping Changjiang Branch Rd, Chongqing 400042, Peoples R China
关键词
Hodgkin lymphoma; CD30; CAR-T; Systematic review; RISK; TRANSPLANTATION;
D O I
10.1186/s12885-024-13400-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundRelapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. This meta-analysis investigates the efficacy and safety of anti-CD30 CAR-T cell therapy for treating R/R cHL.MethodsA systematic literature search of PubMed, Cochrane, Embase, ClinicalTrials.gov, and Web of Science databases was conducted until February 2024. The odds ratio (OR) with a 95% confidence interval (CI) was analysed using Review Manager 5.4. Outcomes including overall response rate (ORR), complete response (CR), partial response (PR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted for meta-analysis. We used the Methodological Index for Non-Randomized Studies (MINORS) to evaluate the quality of the included literature.ResultsA total of 151 participants from 8 records were included. Meta-analysis showed the ORR of CD30 CAR-T cell therapy for R/R cHL was 57% (95%CI 0.36-0.76, P = 0.50), with a CR of 34% (95%CI 0.13-0.64, P = 0.29) and a PR of 32% (95%CI 0.15-0.55, P = 0.12). With the median follow-up range from 9.5 to 71.5 months, the 1-year PFS was 39% (95% CI 0.30-0.49, P = 0.04), and the 1-year OS was 89% (95% CI 0.65-0.97, P = 0.005). The most common hematologic AE was leukopenia (72%, 95% CI: 0.50-0.87), and the most common non-hematological AE was cytokine release syndrome (CRS) (43%, 95% CI: 0.14-0.76). The grade >= 3 AEs was 66% (95%CI 0.06-0.98, I2 = 93%, P = 0.70), 34% (95%CI 0.07-0.78, I2 = 85%, P = 0.51) in neutropenia and thrombocytopenia, respectively. All AEs were tolerable and resolved with treatment.ConclusionCurrent evidence suggests that anti-CD30 CAR-T cell therapy is effective and safe in treating R/R cHL and is worth considering as a viable therapeutic option.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Cytopenia after CAR-T cell therapy: Analysis of 63 patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Qiu, Tingting
    Hu, Luan
    Zhang, Yongtian
    Wang, Ying
    Ma, Sha
    Li, Depeng
    Li, Zhenyu
    Xu, Kailin
    ONCOLOGY LETTERS, 2023, 26 (02)
  • [42] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, : 869 - 876
  • [43] Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma
    Lin, Manisha
    Weiss, Jonathan
    Phillips, Tycel J.
    Sano, Dahlia
    Carty, Shannon A.
    Ghosh, Monalisa
    Ahmed, Iman
    Nachar, Victoria
    Hutton, David
    Karimi, Yasmin H.
    BLOOD, 2023, 142
  • [44] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023,
  • [45] Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis
    Plattel, Wouter J.
    Bergamasco, Aurore
    Trinchese, Fabrizio
    Gavini, Francois
    Bent-Ennakhil, Nawal
    Zomas, Athanasios
    Castillon, Genaro
    Arredondo-Bisono, Teigna
    Cristarella, Tiffany
    Moride, Yola
    von Tresckow, Bastian
    LEUKEMIA & LYMPHOMA, 2021, 62 (14) : 3320 - 3332
  • [46] Comparison of blinatumomab and CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia: a systematic review and meta-analysis
    Zhai, Yixin
    Hong, Ju
    Wang, Jinhuan
    Jiang, Yanan
    Wu, Wenqi
    Lv, Yangyang
    Guo, Jing
    Tian, Linyan
    Sun, Huimeng
    Li, Yuhang
    Li, Cheng
    Zhan, Hongjie
    Zhao, Zhigang
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (1-3) : 67 - 76
  • [47] Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review
    Kattamuri, Lakshmi
    Lal, Bhavesh Mohan
    Vojjala, Nikhil
    Jain, Mansi
    Sharma, Kunal
    Jain, Siddharth
    Al Hadidi, Samer
    RHEUMATOLOGY INTERNATIONAL, 2025, 45 (01)
  • [48] Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
    Li, Lili
    Wang, Luqin
    Liu, Qinhua
    Wu, Zhonghui
    Zhang, Yulong
    Xia, Ruixiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [49] A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?
    Davoodi-Moghaddam, Zeinab
    Jafari-Raddani, Farideh
    Noori, Maryam
    Bashash, Davood
    TRANSLATIONAL ONCOLOGY, 2023, 30
  • [50] Efficacy and Safety of Retreatment with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or CD30-Expressing Peripheral T Cell Lymphoma
    Sano, Dahlia
    Ahmed, Sairah
    Liu, Jingmin
    Knowles, Scott
    Lee, Seung Tae
    BLOOD, 2022, 140 : 12003 - 12004